Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06218914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06218914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
March 22, 2024
Completion date
November 18, 2043
Enrollment
108 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, endometrial cancer, kras g12d, non-small cell lung cancer, pancreatic ductal adenocarcinoma, solid tumor, adult